Avadel Pharmaceuticals plc
AVDL
$14.20
$0.201.43%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 29.74% | 4.17% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 29.74% | 4.17% | |||
| Cost of Revenue | 14.15% | 15.90% | |||
| Gross Profit | 31.60% | 2.93% | |||
| SG&A Expenses | 6.68% | 2.15% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.72% | 3.36% | |||
| Operating Income | 396.03% | 8.98% | |||
| Income Before Tax | 234.14% | 2.44% | |||
| Income Tax Expenses | -4,164.10% | -2.50% | |||
| Earnings from Continuing Operations | 296.44% | 2.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 296.44% | 2.44% | |||
| EBIT | 396.03% | 8.98% | |||
| EBITDA | 557.35% | 17.23% | |||
| EPS Basic | 296.27% | 2.68% | |||
| Normalized Basic EPS | 229.05% | 2.10% | |||
| EPS Diluted | 296.27% | 2.68% | |||
| Normalized Diluted EPS | 225.99% | 2.10% | |||
| Average Basic Shares Outstanding | 0.13% | 0.21% | |||
| Average Diluted Shares Outstanding | 2.57% | 0.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||